Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

British Journal of Haematology

Volumn 151, Issue 5, 2010, Pages 460-468

  Pérez, Benoîte ^a,b   Kosmider, Olivier ^c   Cassinat, Bruno ^b,d   Renneville, Aline ^e   Lachenaud, Julie ^a,b   Kaltenbach, Sophie ^a   Bertrand, Yves ^f   Baruchel, André ^a   Chomienne, Christine ^b,d   Fontenay, Michaela ^c   Preudhomme, Claude ^e   Cavé, Hélène ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^f Institut d'Hemato Oncologie Pediatrique   (France)

Author keywords

ASXL1; CBL; Chronic myelomonocytic leukaemia; JAK2; Juvenile myelomonocytic leukaemia; RUNX1; TET2

Indexed keywords

CBL PROTEIN; DNA BINDING PROTEIN; JANUS KINASE 2; PROTEIN ASXL1; PROTEIN TET2; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CHRONIC MYELOMONOCYTIC LEUKEMIA; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENOME ANALYSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MUTATION; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRESSOR PROTEINS;

EID: 78349249756     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08393.x     Document Type: Article

References (51)

1. Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., Huberman, K., Thomas, S., Dolgalev, I., Heguy, A., Paietta, E., Le Beau, M.M., Beran, M., Tallman, M.S., Ebert, B.L., Kantarjian, H.M., Stone, R.M., Gilliland, D.G., Crispino, J.D. & Levine, R.L. (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 114, 144-147.
2. Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M.J., Larrayoz, M.J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., Della Porta, M.G., Jadersten, M., Killick, S., Hellstrom-Lindberg, E., Cazzola, M. & Wainscoat, J.S. (2010a) Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia, 24, 1062-1065.
3. Boultwood, J., Perry, J., Zaman, R., Fernandez-Santamaria, C., Littlewood, T., Kusec, R., Pellagatti, A., Wang, L., Clark, R.E. & Wainscoat, J.S. (2010b) High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia, 24, 1139-1145.
4. Carbuccia, N., Murati, A., Trouplin, V., Brecqueville, M., Adelaide, J., Rey, J., Vainchenker, W., Bernard, O.A., Chaffanet, M., Vey, N., Birnbaum, D. & Mozziconacci, M.J. (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia, 23, 2183-2186.
5. Carbuccia, N., Trouplin, V., Gelsi-Boyer, V., Murati, A., Rocquain, J., Adelaide, J., Olschwang, S., Xerri, L., Vey, N., Chaffanet, M., Birnbaum, D. & Mozziconacci, M.J. (2010) Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia, 24, 469-473.
6. Castro-Malaspina, H., Schaison, G., Passe, S., Pasquier, A., Berger, R., Bayle-Weisgerber, C., Miller, D., Seligmann, M. & Bernard, J. (1984) Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors. Cancer, 54, 675-686.
7. Chan, R.J., Cooper, T., Kratz, C.P., Weiss, B. & Loh, M.L. (2009) Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leukemia Research, 33, 355-362.
8. Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., Lecluse, Y., Plo, I., Dreyfus, F.J., Marzac, C., Casadevall, N., Lacombe, C., Romana, S.P., Dessen, P., Soulier, J., Viguie, F., Fontenay, M., Vainchenker, W. & Bernard, O.A. (2009) Mutation in TET2 in myeloid cancers. New England Journal of Medicine, 360, 2289-2301.
9. Dunbar, A.J., Gondek, L.P., O'Keefe, C.L., Makishima, H., Rataul, M.S., Szpurka, H., Sekeres, M.A., Wang, X.F., McDevitt, M.A. & Maciejewski, J.P. (2008) 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Research, 68, 10349-10357.
10. Emanuel, P.D. (2008) Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia, 22, 1335-1342.
11. Ernst, T., Chase, A., Zoi, K., Waghorn, K., Hidalgo-Curtis, C., Score, J., Jones, A., Grand, F., Reiter, A., Hochhaus, A. & Cross, N. (2010) Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica, (Epub ahead of print 26 April 2010).
12. Fisher, C.L., Pineault, N., Brookes, C., Helgason, C.D., Ohta, H., Bodner, C., Hess, J.L., Humphries, R.K. & Brock, H.W. (2010) Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood, 115, 38-46.
13. Flotho, C., Valcamonica, S., Mach-Pascual, S., Schmahl, G., Corral, L., Ritterbach, J., Hasle, H., Arico, M., Biondi, A. & Niemeyer, C.M. (1999) RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia, 13, 32-37.
14. Flotho, C., Kratz, C.P. & Niemeyer, C.M. (2007) How a rare pediatric neoplasia can give important insights into biological concepts: a perspective on juvenile myelomonocytic leukemia. Haematologica, 92, 1441-1446.
15. Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Aceto, N., Remy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires-Alj, M., Olschwang, S., Vey, N., Mozziconacci, M.J., Birnbaum, D. & Chaffanet, M. (2008) Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer, 8, 299.
16. Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., Olschwang, S., Xerri, L., Chaffanet, M., Mozziconacci, M.J., Vey, N. & Birnbaum, D. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal Haematology, 145, 788-800.
17. Grand, F.H., Hidalgo-Curtis, C.E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., Kreil, S., Jones, A., Score, J., Metzgeroth, G., Oscier, D., Hall, A., Brandts, C., Serve, H., Reiter, A., Chase, A.J. & Cross, N.C. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood, 113, 6182-6192.
18. Hirsch-Ginsberg, C., LeMaistre, A.C., Kantarjian, H., Talpaz, M., Cork, A., Freireich, E.J., Trujillo, J.M., Lee, M.S. & Stass, S.A. (1990) RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood, 76, 1214-1219.
19. Jankowska, A.M., Szpurka, H., Tiu, R.V., Makishima, H., Afable, M., Huh, J., O'Keefe, C.L., Ganetzky, R., McDevitt, M.A. & Maciejewski, J.P. (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood, 113, 6403-6410.
20. Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J.T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H.M. & Issa, J.P. (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood, 106, 3370-3373.
21. Kales, S.C., Ryan, P.E., Nau, M.M. & Lipkowitz, S. (2010) Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Research, 70, 4789-4794.
22. Kiladjian, J.J., Cassinat, B., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Menot, M.L., Massonnet, G., Dutel, J.L., Ghomari, K., Rousselot, P., Grange, M.J., Chait, Y., Vainchenker, W., Parquet, N., Abdelkader-Aljassem, L., Bernard, J.F., Rain, J.D., Chevret, S., Chomienne, C. & Fenaux, P. (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood, 108, 2037-2040.
23. Koike, K. & Matsuda, K. (2008) Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. British Journal of Haematology, 141, 567-575.
24. Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N., Quesnel, B., Fenaux, P., Bastie, J.N., Beyne-Rauzy, O., Stamatoulas, A., Dreyfus, F., Ifrah, N., De Botton, S., Vainchenker, W., Bernard, O.A., Birnbaum, D., Fontenay, M. & Solary, E. (2009) TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 94, 1676-1681.
25. Kuo, M.C., Liang, D.C., Huang, C.F., Shih, Y.S., Wu, J.H., Lin, T.L. & Shih, L.Y. (2009) RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia, 23, 1426-1431.
26. Lauchle, J.O., Braun, B.S., Loh, M.L. & Shannon, K. (2006) Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric Blood & Cancer, 46, 579-585.
27. Loh, M.L., Sakai, D.S., Flotho, C., Kang, M., Fliegauf, M., Archambeault, S., Mullighan, C.G., Chen, L., Bergstraesser, E., Bueso-Ramos, C.E., Emanuel, P.D., Hasle, H., Issa, J.P., Van Den Heuvel-Eibrink, M.M., Locatelli, F., Stary, J., Trebo, M., Wlodarski, M., Zecca, M., Shannon, K.M. & Niemeyer, C.M. (2009) Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood, 114, 1859-1863.
28. Makishima, H., Cazzolli, H., Szpurka, H., Dunbar, A., Tiu, R., Huh, J., Muramatsu, H., O'Keefe, C., Hsi, E., Paquette, R.L., Kojima, S., List, A.F., Sekeres, M.A., McDevitt, M.A. & Maciejewski, J.P. (2009) Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Journal of Clinical Oncology, 27, 6109-6116.
29. Matsuda, K., Shimada, A., Yoshida, N., Ogawa, A., Watanabe, A., Yajima, S., Iizuka, S., Koike, K., Yanai, F., Kawasaki, K., Yanagimachi, M., Kikuchi, A., Ohtsuka, Y., Hidaka, E., Yamauchi, K., Tanaka, M., Yanagisawa, R., Nakazawa, Y., Shiohara, M., Manabe, A., Kojima, S. & Koike, K. (2007) Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood, 109, 5477-5480.
30. Muramatsu, H., Makishima, H., Jankowska, A.M., Cazzolli, H., O'Keefe, C., Yoshida, N., Xu, Y., Nishio, N., Hama, A., Yagasaki, H., Takahashi, Y., Kato, K., Manabe, A., Kojima, S. & Maciejewski, J.P. (2009) Mutations of E3 ubiquitin ligase Cbl family members but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood, 115, 1969-1975.
31. Niemeyer, C.M., Arico, M., Basso, G., Biondi, A., Cantu Rajnoldi, A., Creutzig, U., Haas, O., Harbott, J., Hasle, H., Kerndrup, G., Locatelli, F., Mann, G., Stollmann-Gibbels, B., Van't Veer-Korthof, E.T., Van Wering, E. & Zimmermann, M. (1997) Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood, 89, 3534-3543.
32. Onida, F., Kantarjian, H.M., Smith, T.L., Ball, G., Keating, M.J., Estey, E.H., Glassman, A.B., Albitar, M., Kwari, M.I. & Beran, M. (2002) Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood, 99, 840-849.
33. Padua, R.A., Guinn, B.A., Al-Sabah, A.I., Smith, M., Taylor, C., Pettersson, T., Ridge, S., Carter, G., White, D., Oscier, D., Chevret, S. & West, R. (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia, 12, 887-892.
34. Pérez, B., Mechinaud, F., Galambrun, C., Ben Romdhane, N., Isidor, B., Philip, N., Derain-Court, J., Cassinat, B., Lachenaud, J., Kaltenbach, S., Salmon, A., Désirée, C., Pereira, S., Menot, M., Royer, N., Fenneteau, O., Baruchel, A., Chomienne, C., Verloes, A. & Cavé, H. (2010) Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukemia (JMML). Journal of Medical Genetics, (Epub ahead of print 12 June 2010).
35. Renneville, A., Quesnel, B., Charpentier, A., Terriou, L., Crinquette, A., Lai, J.L., Cossement, C., Lionne-Huyghe, P., Rose, C., Bauters, F. & Preudhomme, C. (2006) High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia, 20, 2067-2070.
36. Sanada, M., Suzuki, T., Shih, L.Y., Otsu, M., Kato, M., Yamazaki, S., Tamura, A., Honda, H., Sakata-Yanagimoto, M., Kumano, K., Oda, H., Yamagata, T., Takita, J., Gotoh, N., Nakazaki, K., Kawamata, N., Onodera, M., Nobuyoshi, M., Hayashi, Y., Harada, H., Kurokawa, M., Chiba, S., Mori, H., Ozawa, K., Omine, M., Hirai, H., Nakauchi, H., Koeffler, H.P. & Ogawa, S. (2009) Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature, 460, 904-908.
37. Shannon, K.M., Watterson, J., Johnson, P., O'Connell, P., Lange, B., Shah, N., Steinherz, P., Kan, Y.W. & Priest, J.R. (1992) Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood, 79, 1311-1318.
38. Shannon, K.M., O'Connell, P., Martin, G.A., Paderanga, D., Olson, K., Dinndorf, P. & McCormick, F. (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. New England Journal of Medicine, 330, 597-601.
39. Shiba, N., Kato, M., Park, M.J., Sanada, M., Ito, E., Fukushima, K., Sako, M., Arakawa, H., Ogawa, S. & Hayashi, Y. (2010) CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome. Leukemia, 24, 1090-1092.
40. Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G. & Tefferi, A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood, 106, 1207-1209.
41. Sugimoto, Y., Muramatsu, H., Makishima, H., Prince, C., Jankowska, A.M., Yoshida, N., Xu, Y., Nishio, N., Hama, A., Yagasaki, H., Takahashi, Y., Kato, K., Manabe, A., Kojima, S. & Maciejewski, J.P. (2010) Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. British Journal Haematology, 150, 83-87.
42. Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E.D., Theil, K.S., Sekeres, M.A. & Maciejewski, J.P. (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood, 108, 2173-2181.
43. Szpurka, H., Jankowska, A.M., Makishima, H., Bodo, J., Bejanyan, N., Hsi, E.D., Sekeres, M.A. & Maciejewski, J.P. (2010) Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leukemia Research, 34, 969-973.
44. Tartaglia, M., Niemeyer, C.M., Fragale, A., Song, X., Buechner, J., Jung, A., Hahlen, K., Hasle, H., Licht, J.D. & Gelb, B.D. (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics, 34, 148-150.
45. Tefferi, A. (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 24, 1128-1138.
46. Tefferi, A., Lim, K.H. & Levine, R. (2009) Mutation in TET2 in myeloid cancers. New England Journal of Medicine, 361, 1117; author reply 1117-1118.
47. Tono, C., Xu, G., Toki, T., Takahashi, Y., Sasaki, S., Terui, K. & Ito, E. (2005) JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. Leukemia, 19, 1843-1844.
48. Tyner, J.W., Erickson, H., Deininger, M.W., Willis, S.G., Eide, C.A., Levine, R.L., Heinrich, M.C., Gattermann, N., Gilliland, D.G., Druker, B.J. & Loriaux, M.M. (2009) High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood, 113, 1749-1755.
49. De Vries, A.C., Zwaan, C.M. & Van Den Heuvel-Eibrink, M.M. (2010) Molecular basis of juvenile myelomonocytic leukemia. Haematologica, 95, 179-182.
50. Yoshida, N., Yagasaki, H., Xu, Y., Matsuda, K., Yoshimi, A., Takahashi, Y., Hama, A., Nishio, N., Muramatsu, H., Watanabe, N., Matsumoto, K., Kato, K., Ueyama, J., Inada, H., Goto, H., Yabe, M., Kudo, K., Mimaya, J., Kikuchi, A., Manabe, A., Koike, K. & Kojima, S. (2009) Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Pediatric Research, 65, 334-340.
51. Zecca, M., Bergamaschi, G., Kratz, C., Bergstrasser, E., Danesino, C., De Filippi, P., Hasle, H., Lisini, D., Locatelli, F., Pession, A., Sainati, L., Stary, J., Trebo, M., Van Den Heuvel-Eibrink, M., Wojcik, D. & Niemeyer, C.M. (2007) JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia. Leukemia, 21, 367-369.